SynthesisFrontiers in pharmacology2023

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis.

Haosheng Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.